Hybritech Inc.

For an industry that's dependent on innovation, less money is being invested in US biotechnology research and development by venture capital and government sources, and the Pharmaceutical Research & M

This year's Phoenix Lifetime Achievement award winner is interviewed about how he successfully ran both major device and drug businesses and retired early to tell about it. by Stephen Levin The curren

With the wealth of genomics- and proteomics data likely to yield numerous protein-based drug candidates, Big Pharma's continued ambivalence about large molecules may leave some companies playing a ver

Nanogen has spent years developing gene-chip technology. Now it's trying to launch a system in a still-inchoate market that is chaotic, competitive and alluring. Deborah Erickson The promise of genomi